German-based Evotec has partnered with Probiodrug to advance the development operations of drugs targeting major age related diseases such as Alzheimer's disease(AD).
Evotec will support the pre-clinical and clinical development of glutaminyl cyclase(QC)inhibitors by running and validating its existing as well as developing biological assays.
Evotec chief operating officer Dr Mario Polywka said,"We are pleased to enter this collaboration with Probiodrug to use our first class assay development capabilities to support the pre-clinical and clinical development of QC inhibitors in Alzheimer's disease and other indications."
Probiodrug's novel proprietary enzyme target QC plays a key role in the disease mechanism of AD in addition to other diseases.
Probiodrug chief financial officer Hendrik Liebers said,"The collaboration will allow us to focus on the further pre-clinical and clinical development of our programmes in neurodegeneration/AD."
